Lantern Pharma Announces Up to $9.25M Registered Direct Offering

Deal Summary

Lantern Pharma Inc. (NASDAQ: LTRN) entered a definitive agreement for a registered direct offering of 2,135,923 shares at $2.06 per share, raising up to $4.4M in cash with an additional $4.85M potential from warrants, for total proceeds of up to $9.25M. The round is led by Empery Asset Management and includes existing shareholders and a single institutional investor, with closing expected on May 14, 2026. Proceeds will fund working capital and general corporate purposes.